GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Two Trials Disagree.

The Wegovy label states that use in type 1 diabetes has not been evaluated.^[1] Two randomized trials have now evaluated it. In the larger, 36% of people with type 1 diabetes and obesity hit a composite target of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo.^[1] In the smaller, total daily insulin fell by about a third.^[2] Both statements — the label’s and the trials’ — are true, and understanding why is most of what you need here.

Why the label and the literature disagree

A label is not a summary of what is known. It describes what a manufacturer submitted to a regulator and what the regulator approved on that basis. “Has not been evaluated” means no submission covered it — not that no one has studied it.

So prescribing here is off-label, which is legal, common and entirely a clinician’s judgment. It also means the usual scaffolding is missing: no approved dose for this population, no labeled guidance on adjusting insulin alongside it, and no post-marketing surveillance framed around type 1.

What the two trials found

The semaglutide trial’s primary endpoint deserves attention because of how it was built. To count as a success a participant had to achieve all three of: more than 70% of time in range, less than 4% of time below 70 mg/dl, and at least 5% weight loss. That is a demanding composite, deliberately including a safety condition rather than only benefits. 36% cleared it. Nobody on placebo did.^[1]

The safety question that actually matters

In type 1 diabetes the fear is not weight or glucose control. It is diabetic ketoacidosis — the complication that ended enthusiasm for SGLT2 inhibitors in this population after they were shown to raise it. Anything that reduces insulin requirements in someone who makes no insulin invites that question.

No diabetic ketoacidosis was reported in either trial. Neither was remotely large enough to rule it out.

Severe hypoglycemia was also unchanged: two events in the semaglutide group and two in the placebo group.^[1] That is reassuring on the concern most people raise first, and it comes from 72 people over 26 weeks. Rare events need thousands of participant-years, and this literature has a few dozen.

Who these trials were

Both enrolled people with type 1 diabetes and obesity — BMI 30 or above — which is now common and was not always. The semaglutide trial required participants to be using an automated insulin delivery system, meaning a pump adjusting doses algorithmically.

That last detail limits how far the result travels. Automated delivery absorbs a great deal of variability, and a system that adjusts insulin every few minutes is a different safety context from injections on a fixed schedule. The reassuring hypoglycemia numbers were produced with that safety net in place.

Where this leaves things

• The evidence is real, small and short. 72 people for 26 weeks and 24 for 12 weeks is a beginning, not a basis for routine use.
• The weight and insulin effects are substantial and are what would make this attractive to someone managing both conditions.
• The DKA question is open, not answered. Absence in 96 people is weak evidence about a rare event.
• Nothing here is approved, so cost and coverage will be harder — our insurance section covers what plans publish about off-label use.

Our low blood sugar article covers the hypoglycemia mechanics in more detail, including why these drugs are poor causes of it on their own and what changes when insulin is in the picture.

In young people, the weight moved and the glucose did not

A single-center retrospective study followed 24 adolescents and young adults aged 10 to 20 with type 1 diabetes and obesity who were prescribed a GLP-1 between 2019 and 2024.^[4] What happened splits cleanly in two.

Twenty-four patients at one center, retrospectively, across five different drugs, is a small and heterogeneous basis for anything — and it is roughly what exists for this population. Three quarters were girls and young women, two thirds had public insurance, and most were using continuous monitors and pumps, which describes a group already engaged with intensive management.

What a large real-world cohort adds

The trials above measured glucose control and insulin dose. A 2026 propensity-matched analysis of 4,088 people per group with type 1 diabetes looked at harder outcomes, and found GLP-1-based therapy associated with lower all-cause mortality (HR 0.67), heart failure (HR 0.38), a composite cardiovascular endpoint (HR 0.61) and all-cause hospitalization (HR 0.70).^[3]

Two safety results matter more here than the efficacy ones. Diabetic ketoacidosis was not increased — the single largest fear about using these drugs in type 1 diabetes. And hypoglycemia risk was lower, at a hazard ratio of 0.72. Fewer than ten pancreatitis events occurred in either group.^[3]